Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PTC Therapeutics ( (PTCT) ) has issued an announcement.
On January 12, 2026, PTC Therapeutics reported preliminary unaudited 2025 results showing approximately $823.4 million in total product and royalty revenue, above prior guidance, including $587.8 million in product revenue and $112.1 million from its newly launched Sephience, which generated $92.5 million in fourth-quarter sales alone and reached 946 patients worldwide by year-end. The company ended 2025 with about $1.94 billion in cash and securities, completed the sale of its remaining Evrysdi royalty stream for up to $300 million in consideration while retaining a potential $150 million milestone, advanced its pipeline with FDA alignment on a Phase 3 Huntington’s disease trial for votoplam and continued regulatory engagement on vatiquinone and Translarna, and issued 2026 guidance calling for $700 million to $800 million in product revenue and GAAP R&D and SG&A expenses of $775 million to $815 million, underscoring both strong launch momentum and sustained investment in late-stage programs as it moves toward cash-flow breakeven.
The most recent analyst rating on (PTCT) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.
Spark’s Take on PTCT Stock
According to Spark, TipRanks’ AI Analyst, PTCT is a Neutral.
The score is driven by strong operational momentum (high TTM revenue growth, strong margins, and positive earnings-call guidance around Sephience) and an inexpensive P/E. Offsetting factors are balance-sheet risk from negative equity/high leverage and only neutral technical momentum.
To see Spark’s full report on PTCT stock, click here.
More about PTC Therapeutics
PTC Therapeutics is a global biopharmaceutical company focused on discovering, developing and commercializing clinically differentiated medicines for children and adults with rare disorders, leveraging its ability to innovate and to globally commercialize products to support a diversified pipeline of transformative therapies.
Average Trading Volume: 1,544,995
Technical Sentiment Signal: Buy
Current Market Cap: $6.17B
For detailed information about PTCT stock, go to TipRanks’ Stock Analysis page.